Enabling biotech with strategic AI
Coescent is a strategy development and value discovery firm focusing on complex problem solving and innovation at the intersection of technical, scientific, and commercial priorities by bridging the biopharma AI technical-strategic gap.
To discuss partnering with Coescent on strategy development and value discovery, reach out.
- Wet-lab-first companies
- Determine how AI can create new strategic and scientific value.
- AI-first companies
- Translate technical differentiation into biopharma market differentiation.
Where and how could AI be integrated to create value?
Custom proprietary integration of biological modality AI and agentic workflows into wet-lab R&D can expand the discovery and design space, accelerate R&D timelines, and enhance future partnership potential. With a large and growing landscape of open-source and proprietary models as well as model infrastructure ecosystems, it can be challenging to identify which, if any, solutions are best suited for or can be adapted to a company's specific platform needs and resource constraints.
Coescent works across the spectrum of structural, cellular, and agentic AI to identify targeted approaches to complex and unique R&D needs that drive strategic value. This includes custom lab-in-the-loop setups, build vs. buy vs. partner strategy, and bespoke agentic workflows. The approach is science- and value-led, supported by technological breadth and depth.
How can technical differentiation convert to market advantage?
With a rapidly evolving competitive landscape and a crowded capability space, AI-first companies must ensure that their development program and product vision are keenly attuned to biopharma needs and provide clear differentiating value. At Coescent, engineering, product, and partnerships are treated as an intertwined whole. Engagements are designed to pinpoint problems with market-product fit and identify how technical differentiation can be converted into product differentiation to open new market and partnership opportunities.
Engagement focus areas are R&D-targeting products and capabilities, including molecular design capabilities, single-cell foundation models, and agentic AI directed at research, discovery, and wet-lab integration.
Which data, models, or workflows could unlock new partnerships?
A company's digital assets can serve a dual purpose of internal R&D enhancement and new capital flow opportunities, but it is critical to determine data-model-market fit, balance competition and differentiation, and identify what internal investment is required to generate additional revenue from existing data or in silico capabilities. Engagements apply a combined technical-commercial approach to identify internal candidate assets for external repurposing and design a development and partnership strategy.
Can new AI developments help navigate a strategic inflection point?
When companies find themselves at a pivot point, either due to negative R&D signals or a change in the competitive landscape, they may need to rethink their core value proposition and look for pivot options that ensure their continued existence as an attractive investment target. Coescent partners with companies navigating strategic inflection points to identify AI-driven pivots that can reposition the company for continued innovation and differentiation. Engagements combine strategic planning and scientific exploration to surface and pressure test new directions and translate them into strategic priorities.
To discuss partnering with Coescent on strategy development and value discovery, reach out.